Literature DB >> 29794210

Medication Regimens for Managing COPD Exacerbations.

Nirupama Putcha1, Robert A Wise2.   

Abstract

Exacerbations are a hallmark feature of COPD and contribute to morbidity and mortality. There is general agreement that the pharmacotherapy of COPD exacerbations includes bronchodilators, corticosteroids, and antibiotics. Strong evidence exists for the benefit of corticosteroids for exacerbations and of antibiotics in the acute hospital setting. There remains considerable uncertainty, however, in the best drug selection, dose, route, and duration of treatment. This article reviews the evidence base and expert recommendations for drug treatment of COPD exacerbations in the out-patient and in-patient settings.
Copyright © 2018 by Daedalus Enterprises.

Entities:  

Keywords:  COPD; antibiotics; bronchodilators; corticosteroid; pharmacotherapy

Mesh:

Substances:

Year:  2018        PMID: 29794210      PMCID: PMC6818681          DOI: 10.4187/respcare.05912

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  55 in total

1.  The COPD Pipeline XXXIII.

Authors:  Nicholas Gross
Journal:  Chronic Obstr Pulm Dis       Date:  2017-01-09

2.  Assessment of airway neutrophils by sputum colour: correlation with airways inflammation.

Authors:  R A Stockley; D Bayley; S L Hill; A T Hill; S Crooks; E J Campbell
Journal:  Thorax       Date:  2001-05       Impact factor: 9.139

3.  Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Peter K Lindenauer; Penelope S Pekow; Maureen C Lahti; Yoojin Lee; Evan M Benjamin; Michael B Rothberg
Journal:  JAMA       Date:  2010-06-16       Impact factor: 56.272

Review 4.  Bronchodilators delivered by nebuliser versus pMDI with spacer or DPI for exacerbations of COPD.

Authors:  Wouter H van Geffen; W R Douma; Dirk Jan Slebos; Huib A M Kerstjens
Journal:  Cochrane Database Syst Rev       Date:  2016-08-29

5.  Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Authors:  Henrik Watz; Kay Tetzlaff; Emiel F M Wouters; Anne Kirsten; Helgo Magnussen; Roberto Rodriguez-Roisin; Claus Vogelmeier; Leonardo M Fabbri; Pascal Chanez; Ronald Dahl; Bernd Disse; Helen Finnigan; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2016-04-07       Impact factor: 30.700

6.  Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.

Authors:  Jin-Ping Zheng; Fu-Qiang Wen; Chun-Xue Bai; Huan-Ying Wan; Jian Kang; Ping Chen; Wan-Zhen Yao; Li-Jun Ma; Xia Li; Luca Raiteri; Marco Sardina; Yi Gao; Bai-Song Wang; Nan-Shan Zhong
Journal:  Lancet Respir Med       Date:  2014-01-30       Impact factor: 30.700

7.  Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.

Authors:  D C Levin; K S Little; K R Laughlin; J M Galbraith; P M Gustman; D Murphy; J A Kram; G Hardie; C Reuter; D Ostransky; K McFarland; T L Petty; W Silvers; S I Rennard; M Mueller; L H Repsher; R L Zuwallack; R Vale
Journal:  Am J Med       Date:  1996-01-29       Impact factor: 4.965

Review 8.  Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.

Authors:  S Appleton; T Jones; P Poole; L Pilotto; R Adams; T J Lasserson; B Smith; J Muhammad
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

9.  Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.

Authors:  Vamsi Bollu; Frank R Ernst; John Karafilidis; Krithika Rajagopalan; Scott B Robinson; Sidney S Braman
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-12-05

Review 10.  COPD exacerbations: defining their cause and prevention.

Authors:  Jadwiga A Wedzicha; Terence A R Seemungal
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.